MEI Pharma Bets $100m on Litecoin as Charlie Lee Joins Board
9 Articles
9 Articles
GSR Leads $100M Private Placement into Nasdaq-listed MEI Pharma to Launch First Institutional Litecoin Treasury Strategy Alongside Charlie Lee - Tech Startups
NEW YORK, United States, 18th July 2025, Chainwire The post GSR Leads $100M Private Placement into Nasdaq-listed MEI Pharma to Launch First Institutional Litecoin Treasury Strategy Alongside Charlie Lee first appeared on Tech Startups.
NEW: MEI Pharma Becomes First Public Company to Hold Litecoin in Treasury
MEI Pharma Inc. (NASDAQ:MEIP) has announced a $100 million private investment to acquire Litecoin, making it the first publicly traded company to adopt LTC as its primary treasury reserve asset. The company is selling 29,239,767 shares at $3.42 each. Charlie Lee, the creator of Litecoin, and GSR are leading the investment. Lee will join MEI’s board of directors, replacing Taheer Datoo upon closing. GSR will serve as MEI’s digital asset and treas…
GSR Invests $100M in MEI Pharma to Launch First Institutional Litecoin Treasury with Charlie Lee
GSR, a leading capital markets partner in the crypto industry, has announced a landmark $100 million private placement into MEI Pharma, Inc. (NASDAQ: MEIP), marking a bold step toward positioning Litecoin (LTC) as an institutional-grade treasury asset. As part of the strategic deal, GSR will assume the role of both strategic advisor and digital asset […]
MEI Pharma Commits $100M to Litecoin Treasury Strategy: Can LTC Price 10x? - Blockonomi
TLDR: MEI Pharma sets up $100M Litecoin treasury with major institutional backing. Litecoin creator Charlie Lee joins MEI Pharma board to lead crypto expansion. GSR and Titan Partners collaborate to execute LTC treasury strategy. Move signals Litecoin’s entry into corporate finance and long-term adoption. MEI Pharma is taking a big step into crypto. The company is building a $100 million Litecoin treasury and bringing in major players to lead …
Coverage Details
Bias Distribution
- 50% of the sources lean Left, 50% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium